“Being told that my breast cancer had spread was the worst news imaginable. At the age of 39, I felt like I had everything to live for. I loved life, my children, friends and family. I certainly didn’t want the children to lose their mother, like I had.”
“There is a grieving process that takes place with secondary diagnosis. Grieving for the life I thought I would lead. I have learnt to appreciate, what I have, rather than focusing on what I’ve lost. I remain passionate about many aspects of my life … my children give me great strength to pursue every avenue in order to survive.”
“They have been asking loads of questions. It’s heartbreaking when they ask if you’re going to die. And my daughter Ava asks me all the time – ‘Mum, will it happen to me? Now you’ve had it and Aunty Jane, will I be next?”
“There is no cure for secondary breast cancer, but I’m holding out for one. I want my children’s future to be a different story to the generations of women who came before me.”
“Breast cancer is the most common life-threatening cancer affecting women in Australia, with over 3,000 deaths a year. This will only change with your support. Thank you for making a difference to the lives of so many.” Click here for Rachel's full story.
Dr. Clare Slaney, breaking new ground in breast cancer research.
A research project funded by the National Breast Cancer Foundation (NBCF) is on the verge of a significant breakthrough for the prevention and treatment of secondary breast cancer. Learn about Dr. Slaney's previous work with NBCF above.
NBCF-funded researcher Dr Clare Slaney and her team are breaking new ground in the field of cancer immunotherapy, focusing on a novel approach called T Cell therapy. This new method involves a transfusion of white blood cells, which are genetically modified to attack breast cancer cells, combined with an injection of a vaccine that also has the power to attack cancer cells.
Dr Slaney’s ultimate goal is to trigger the body’s immune system to fight and kill cancer cells, specifically secondary breast cancer cells. Click here to continue reading.